Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02572245 · ClinicalTrials.gov registry record · Phase 1
A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects
A Phase 1 study of Healthy Subjects, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 1
- Study location
NCT02572245: Completed Phase 1 study of Healthy Subjects, sponsored by Pfizer.
NCT02572245 is a Phase 1 study of Healthy Subjects that has completed, run by Pfizer. The registered enrollment target is 164 participants, above the 126-participant average among 69 other Healthy Subjects trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02572245, a Phase 1 study of Healthy Subjects, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study comparing adalimumab Pfizer (PF-06410293) administered as a subcutaneous(SC) injection using a pre-filled syringe (PFS) or pre-filled pen in healthy adult subjects
Conditions Studied
Interventions
- DEVICE PF-06410293 PFS
- DEVICE PF-06410293 PFP
Study Locations (1)
Texas
- ICON Early Phase Services, LLC - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2016-01 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT02572245 record still lists
NCT02572245 is an interventional study that assigns participants to a tested intervention. The registered 164 participants enrollment target is mid-sized for trials with a published cap, above the 126-participant average among 69 other Healthy Subjects trials with a reported enrollment target (30% higher).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which PF-06410293 PFS is the first listed.
NCT02572245 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02572245 about?
NCT02572245 is a clinical study titled "A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects". This is a study comparing adalimumab Pfizer (PF-06410293) administered as a subcutaneous(SC) injection using a pre-filled syringe (PFS) or pre-filled pen in healthy adult subjects
What is the current status of trial NCT02572245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2016-01. Estimated completion is 2016-05.
What conditions does trial NCT02572245 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT02572245?
The interventions under investigation include: PF-06410293 PFS (DEVICE), PF-06410293 PFP (DEVICE).
Who is sponsoring clinical trial NCT02572245?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02572245 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02572245's enrollment target sits among peer trials
164 8th of 69 higher than 62 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04891289 · 164 participants · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- NCT04893226 · 164 participants · NA
Time-Restricted Feeding Intervention in Metabolically-Unhealthy Postmenopausal Women
- NCT05270213 · 164 participants · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- NCT05543681 · 164 participants · Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia